



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider tandem autologous hematopoietic cell transplantation (HCT) or transplant with sequential high-dose chemotherapy for the treatment of testicular tumors either as salvage therapy or with platinum-refractory disease to be **eligible for coverage.****

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider single autologous hematopoietic cell transplantation (HCT) as salvage therapy for germ cell tumors to be **eligible for coverage**** when patient selection criteria are met.

Patient Selection Criteria

The use of single autologous hematopoietic cell transplantation (HCT) as salvage therapy for germ-cell tumors may be considered **eligible for coverage**** when **ANY** of the following criteria are met:

- In individuals with favorable prognostic factors that have failed a previous course of conventional-dose salvage chemotherapy; **OR**

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

- In individuals with unfavorable prognostic factors as initial treatment of first relapse (i.e., without a course of conventional-dose salvage chemotherapy) and in individuals with platinum-refractory disease.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of single autologous hematopoietic cell transplantation (HCT) as salvage therapy to treat individuals with germ-cell tumors when patient selection criteria are not met to be **investigational**.*

Based on review of available data, the Company considers autologous hematopoietic cell transplantation (HCT) as a component of first-line treatment for germ cell tumors to be **investigational**.*

Based on review of available data, the Company considers allogeneic hematopoietic cell transplantation (HCT) to treat germ cell tumors, including, but not limited, to its use as therapy after a prior failed autologous HCT to be **investigational**.*

Policy Guidelines

The favorable and unfavorable prognostic factors listed below are derived from the current National Comprehensive Cancer Network guidelines and DeVita et al. textbook *Cancer: Principles and Practice of Oncology* (2015, pp. 988-1004).

Individuals with favorable prognostic factors include those with a testis or retroperitoneal primary site, a complete response to initial chemotherapy, low levels of serum markers, and low-volume disease. Individuals with unfavorable prognostic factors are those with an extra testicular primary site, an incomplete response to initial therapy, high levels of serum markers, high-volume disease, or relapsing mediastinal nonseminomatous germ cell tumors.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

Background/Overview

Germ Cell Tumors

Germ cell tumors are composed primarily of testicular neoplasms as well as ovarian and extragonadal germ cell tumors (no primary tumor in either testis or ovary). Germ cell tumors are classified by their histology, stage, prognosis, and response to chemotherapy.

The most common testicular germ cell tumors are seminomas; all other histologic types are collectively referred to as nonseminomatous tumors. Nonseminomatous tumor types include embryonal cell tumor, yolk sac tumor, and teratomas. Malignant germ cell tumors of ovarian origin are classified as dysgerminomas or nondysgerminomas. Similarly, nondysgerminomas include immature teratomas, embryonal cell tumors, yolk sac tumor, polyembryoma, and mixed germ cell tumors.

Staging

Stage depends on location and extent of the tumor, using the American Joint Committee on Cancer's TNM system. TNM stages, modified by serum concentrations of markers for tumor burden (S0 to 3) when available, are grouped by similar prognoses. Markers used for germ cell tumors include human β -chorionic gonadotropin, lactate dehydrogenase, and α -fetoprotein. However, most patients with pure seminoma have normal α -fetoprotein concentrations. For testicular tumors, stages IA to B tumors are limited to the testis (no involved nodes or distant metastases) and no marker elevations (S0); stages IIA to C have increasing size and number of tumor-involved lymph nodes, and at least 1 marker moderately elevated above the normal range (S1), and stages IIIA to C have distant metastases and/or marker elevations greater than specified thresholds (S2 to 3).

Germ cell tumors also are divided into good-, intermediate-, or poor-risk categories based on histology, site, extent of the primary tumor, and serum marker levels. Good-risk pure seminomas can be at any primary site but are without nonpulmonary visceral metastases or marker elevations. Intermediate-risk pure seminomas have nonpulmonary visceral metastases with or without elevated human chorionic gonadotropin and/or lactate dehydrogenase. There are no poor-risk pure seminomas, but mixed histology tumors and seminomas with elevated α -fetoprotein (due to the mixture with nonseminomatous components) are managed as nonseminomatous germ cell tumors. Good- and intermediate-risk nonseminomatous germ cell tumors have testicular or retroperitoneal tumors without nonpulmonary visceral metastases, and either S1 (good-risk) or S2

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

(intermediate) levels of marker elevations. Poor-risk tumors have mediastinal primary tumors, or nonpulmonary visceral metastases, or the highest level (S3) of marker elevations.

Hematopoietic Cell Transplantation

Hematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allogeneic HCT [allo-HCT]). These cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allogeneic stem cell transplantation, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

Conditioning for Hematopoietic Cell Transplantation

Conventional Conditioning

The conventional ("classical") practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease (GVHD), which increases susceptibility to opportunistic infections.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient's disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning treatments. Although the definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and non-relapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. RIC regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term *reduced-intensity conditioning* will refer to all conditioning regimens intended to be nonmyeloablative.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Therapy for germ cell tumors is generally dictated by several factors, including disease stage, tumor histology, primary site of tumor, and response to chemotherapy. Patients with unfavorable prognostic factors may be candidates for hematopoietic cell transplantation (HCT).

Summary of Evidence- Intro

For individuals who have previously untreated germ cell tumors who receive autologous HCT as first-line therapy, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are overall survival (OS), disease-specific survival (DSS), and treatment-related mortality and morbidity. Results from RCTs have shown that autologous HCT as initial therapy for germ cell tumors did not significantly improve outcomes compared with alternative therapy (eg, standard-dose chemotherapy). Study sample sizes were relatively small and might have been underpowered to detect differences between groups. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have relapsed or refractory germ cell tumors who receive autologous HCT, the evidence includes an RCT and several case series. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. The single published RCT did not find improved outcomes with high-dose chemotherapy (HDC) and autologous HCT compared with standard-dose HCT. Case series had a wide range of sample sizes. Progression-free and OS rates varied by prior treatment experience, prognostic factors, number of high-dose chemotherapy and autologous stem cell transplantation cycles, and whether additional consolidation treatment such as radiation therapy was included. However, 2- and 3-year progression-free survival rates of 50% to 60% have consistently been achieved. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have germ cell tumors who receive tandem autologous transplantation and sequential HDC, the evidence includes an RCT, several retrospective cohort studies, and a comparative effectiveness review. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. The RCT reported a higher rate of treatment-related mortality with sequential HDC compared with single HDC. However, 5 -year survival outcomes did not differ significantly between groups. Overall, the available studies have included heterogeneous patient populations, in different

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

salvage treatment settings (ie, first vs. subsequent salvage therapy), and have lacked a universally accepted prognostic scoring system to risk-stratify patients. Tandem autologous transplant or transplant with sequential HDC has not shown a benefit in patients with primary mediastinal germ cell tumors. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have germ cell tumors who receive allogeneic HCT, the evidence includes a case report. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. There were no RCTs or nonrandomized comparative studies evaluating allogeneic HCT for germ cell tumors. One 2007 case report has described successful treatment of a refractory mediastinal germ cell tumor with allogeneic HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2010 Input

In response to requests, input was received from 3 physician specialty societies, 3 academic medical centers, and 5 Blue Distinction Centers for Transplants while this policy was under review in 2010. There was general agreement with the policy statements regarding the use of single autologous hematopoietic cell transplantation (HCT) as salvage therapy, the use of autologous HCT as first-line treatment, and the use of allogeneic HCT. Seven reviewers felt that tandem autologous transplant or transplant with sequential HCT is medically necessary for patients as salvage therapy or with platinum-refractory disease; 2 reviewers felt that tandem transplant or sequential high-dose chemotherapy was investigational.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056
Original Effective Date: 01/28/2002
Current Effective Date: 05/13/2024

representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network

Current NCCN guidelines on ovarian cancer (v2.2023) state that high-dose chemotherapy with stem cell support is among preferred regimens as potentially curative therapy for recurrent malignant germ cell tumors.

Current National Comprehensive Cancer Network (NCCN) guidelines on testicular cancer (v1.2023) state that second-line chemotherapy regimens for metastatic germ cell tumors include high-dose chemotherapy with stem cell support.

American Society for Transplantation and Cellular Therapy

In 2020, guidelines by the American Society for Transplantation and Cellular Therapy were published on indications for autologous and allogeneic HCT. Recommendations were intended to describe the current consensus on the use of HCT within and outside of the clinical trial setting. Recommendations on germ cell tumors are listed in Table 1.

Table 1. Recommendations on Allogeneic and Autologous Hematopoietic Cell Transplantation

Indications	Allogeneic HCT	Autologous HCT
Pediatric		
Germ cell tumor, relapse	D	C
Germ cell tumor, refractory	D	C
Adult		
Germ cell tumor, relapse	N	S
Germ cell tumor, refractory	N	S

HCT: hematopoietic cell transplantation; C: clinical evidence available, standard of care; D: developmental (ie promising); N: not generally recommended; S: standard of care.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056
Original Effective Date: 01/28/2002
Current Effective Date: 05/13/2024

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this policy are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT02375204	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	420	Jun 2024
NCT00936936	High-dose Chemotherapy for Poor-prognosis Relapsed Germ-cell Tumors	64	Mar 2024
<i>Unpublished</i>			
NCT00432094	Autologous Peripheral Blood Stem Cell Transplant for Germ-Cell Tumors	23	Mar 2021

NCT: national clinical trial.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

References

1. Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. *BMJ*. Nov 28 2022; 379: e070499. PMID 36442868
2. Veneris JT, Mahajan P, Frazier AL. Contemporary management of ovarian germ cell tumors and remaining controversies. *Gynecol Oncol*. Aug 2020; 158(2): 467-475. PMID 32507650
3. Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). *Ann Oncol*. May 2011; 22(5): 1054-1061. PMID 21059637
4. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. *J Clin Oncol*. Jan 20 2007; 25(3): 247-56. PMID 17235042
5. Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. *Eur Urol*. Mar 2007; 51(3): 739-46; discussion 747-8. PMID 17084512
6. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. *Ann Oncol*. Jul 2005; 16(7): 1152-9. PMID 15928070
7. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol*. Feb 1997; 15(2): 594-603. PMID 9053482
8. Zschäbitz S, Distler FA, Krieger B, et al. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. *Oncotarget*. Apr 27 2018; 9(32): 22537-22545. PMID 29854297
9. Adra N, Abonour R, Althouse SK, et al. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. *J Clin Oncol*. Apr 01 2017; 35(10): 1096-1102. PMID 27870561
10. Nieto Y, Tu SM, Bassett R, et al. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. *Ann Oncol*. Dec 2015; 26(12): 2507-8. PMID 26487577

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

11. Baek HJ, Park HJ, Sung KW, et al. Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. *J Neurooncol.* Sep 2013; 114(3): 329-38. PMID 23824533
12. Seftel MD, Paulson K, Doocey R, et al. Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study. *Bone Marrow Transplant.* Jun 2011; 46(6): 852-7. PMID 21042312
13. Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. *J Clin Oncol.* Jul 01 2007; 25(19): 2778-84. PMID 17602082
14. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. *J Clin Oncol.* Mar 10 2012; 30(8): 800-5. PMID 22291076
15. Lotz JP, Bui B, Gomez F, et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. *Ann Oncol.* Mar 2005; 16(3): 411-8. PMID 15659420
16. Agrawal V, Abonour R, Abu Zaid M, et al. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation. *Cancer.* Oct 15 2021; 127(20): 3751-3760. PMID 34260067
17. Lazarus HM, Stiff PJ, Carreras J, et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. *Biol Blood Marrow Transplant.* Jul 2007; 13(7): 778-89. PMID 17580256
18. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med.* Jul 26 2007; 357(4): 340-8. PMID 17652649
19. Suleiman Y, Siddiqui BK, Brames MJ, et al. Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors. *Biol Blood Marrow Transplant.* Jan 2013; 19(1): 161-3. PMID 22892555
20. Pal SK, Yamzon J, Sun V, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors. *Clin Genitourin Cancer.* Jun 2013; 11(2): 121-7. PMID 23062817

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

21. Ratko TA, Belinson SE, Brown HM, et al. Hematopoietic Stem-Cell Transplantation in the Pediatric Population (No. 12-EHC018-EF). Rockville, MD: Agency for Healthcare Research and Quality; 2012.
22. Goodwin A, Gurney H, Gottlieb D. Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effect. Intern Med J. Feb 2007; 37(2): 127-9. PMID 17229257
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, v2.2023. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer, v1.2023. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
25. Kanate AS, Majhail NS, Savani BN, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. Jul 2020; 26(7): 1247-1256. PMID 32165328

Policy History

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

- | | |
|------------|--|
| 12/06/2001 | Medical Policy Committee review |
| 01/28/2002 | Managed Care Advisory Council approval |
| 06/24/2002 | Format revision. Policy addresses only Germ Cell Tumors. Replaces high dose chemotherapy with hematopoietic stem cell support. |
| 03/31/2004 | Medical Director review |
| 04/20/2004 | Medical Policy Committee review. Format revision. No substance change to policy. |
| 04/26/2004 | Managed Care Advisory Council approval |
| 05/03/2005 | Medical Director review |
| 05/17/2005 | Medical Policy Committee review. Format revision. Policy statement corrected to reflect "that HDC and autologous SCS as initial treatment (i.e., in lieu of an initial course of conventional chemotherapy) of poor-risk germ cell tumors or as initial treatment of a first relapse (i.e., in lieu of a course of conventional chemotherapy) is investigational". |

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

05/23/2005	Managed Care Advisory Council approval
05/03/2006	Medical Director review
05/17/2006	Medical Policy Committee approval. Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
10/10/2007	Medical Director review
10/17/2007	Medical Policy Committee approval. No change to coverage eligibility.
10/01/2008	Medical Director review
10/22/2008	Medical Policy Committee approval. No change to coverage eligibility.
10/01/2009	Medical Policy Committee approval
10/14/2009	Medical Policy Implementation Committee approval. Title changed from “High-Dose Chemotherapy with Stem Cell Support for Germ Cell Tumors” to “Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell Tumors”. No change to coverage eligibility.
10/14/2010	Medical Policy Committee review
10/20/2010	Medical Policy Implementation Committee approval. Terminology changed in coverage statements. Coverage statements changed to indicate that tandem-sequential autologous stem-cell transplantation may be considered eligible for coverage in certain types of testicular cancers.
10/06/2011	Medical Policy Committee review
10/19/2011	Medical Policy Implementation Committee approval. “Based on review of available data, except as noted above for treatment of certain testicular tumors, the Company considers tandem or sequential autologous hematopoietic stem-cell transplantation to treat germ-cell tumors of any stage to be investigational” was deleted from coverage.
10/11/2012	Medical Policy Committee review
10/31/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2013	Coding updated
10/03/2013	Medical Policy Committee review
10/16/2013	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/06/2014	Medical Policy Committee review

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

11/21/2014	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015	Medical Policy Committee review
11/16/2015	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2016	Medical Policy Committee review
11/16/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-10 Diagnosis Codes
11/02/2017	Medical Policy Committee review
11/15/2017	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/08/2018	Medical Policy Committee review
11/21/2018	Medical Policy Implementation Committee approval. One policy statement was reworded, from "Tandem or sequential autologous HCT may be considered eligible for coverage for the treatment of testicular tumors either as salvage therapy or with platinum-refractory disease" to "Tandem autologous HCT or transplant with sequential high-dose chemotherapy may be considered eligible for coverage for the treatment of testicular tumors either as salvage therapy or with platinum-refractory disease."
11/07/2019	Medical Policy Committee review
11/13/2019	Medical Policy Implementation Committee approval. No change to coverage.
04/02/2020	Medical Policy Committee review
04/08/2020	Medical Policy Implementation Committee approval. No change to coverage.
04/01/2021	Medical Policy Committee review
04/14/2021	Medical Policy Implementation Committee approval. No change to coverage.
04/07/2022	Medical Policy Committee review
04/13/2022	Medical Policy Implementation Committee approval. No change to coverage Coding update
04/06/2023	Medical Policy Committee review
04/12/2023	Medical Policy Implementation Committee approval. Replaced "patients" with "individuals" in the coverage section. Coverage eligibility unchanged.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

04/04/2024 Medical Policy Committee review

04/10/2024 Medical Policy Implementation Committee approval. No change to coverage.

Next Scheduled Review Date: 04/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)®, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243
HCPCS	S2140, S2142, S2150
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy # 00056

Original Effective Date: 01/28/2002

Current Effective Date: 05/13/2024

- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.